Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

389 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acute chemotherapy-related toxicity is not increased in BRCA1 and BRCA2 mutation carriers treated for breast cancer in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Smith I, Gui G; Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: barr l. Clin Cancer Res. 2006 Dec 1;12(23):7033-8. doi: 10.1158/1078-0432.CCR-06-1246. Clin Cancer Res. 2006. PMID: 17145825
Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.
Shanley S, McReynolds K, Ardern-Jones A, Ahern R, Fernando I, Yarnold J, Evans G, Eccles D, Hodgson S, Ashley S, Ashcroft L, Tutt A, Bancroft E, Short S, Gui G; Breast Unit of the Royal Marsden NHS Foundation Trust; Barr L, Baildam A, Howell A, Royle G, Pierce L, Easton D, Eeles R. Shanley S, et al. Among authors: barr l. Clin Cancer Res. 2006 Dec 1;12(23):7025-32. doi: 10.1158/1078-0432.CCR-06-1244. Clin Cancer Res. 2006. PMID: 17145824
Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers.
Marcinkute R, Woodward ER, Gandhi A, Howell S, Crosbie EJ, Wissely J, Harvey J, Highton L, Murphy J, Holland C, Edmondson R, Clayton R, Barr L, Harkness EF, Howell A, Lalloo F, Evans DG. Marcinkute R, et al. Among authors: barr l. J Med Genet. 2022 Feb;59(2):133-140. doi: 10.1136/jmedgenet-2020-107356. Epub 2021 Feb 10. J Med Genet. 2022. PMID: 33568438
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM. Bundred NJ, et al. Among authors: barr l. Clin Cancer Res. 2010 Mar 1;16(5):1605-12. doi: 10.1158/1078-0432.CCR-09-1623. Epub 2010 Feb 23. Clin Cancer Res. 2010. PMID: 20179229 Clinical Trial.
389 results